Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial

Jeffrey S Hoch, Annette Hay, Wanrudee Isaranuwatchai, Kednapa Thavorn, Natasha B. Leighl, Dongsheng Tu, Logan Trenaman, Carolyn S Dewa, Chris O'Callaghan, Joseph Pater, Derek Jonker, Bingshu E. Chen, Nicole Mittmann

Research output: Contribution to journalArticle

Abstract

Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.

Original languageEnglish (US)
Article number552
JournalBMC Cancer
Volume19
Issue number1
DOIs
StatePublished - Jun 7 2019
Externally publishedYes

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Net benefit regression

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial'. Together they form a unique fingerprint.

  • Cite this

    Hoch, J. S., Hay, A., Isaranuwatchai, W., Thavorn, K., Leighl, N. B., Tu, D., Trenaman, L., Dewa, C. S., O'Callaghan, C., Pater, J., Jonker, D., Chen, B. E., & Mittmann, N. (2019). Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial. BMC Cancer, 19(1), [552]. https://doi.org/10.1186/s12885-019-5779-x